Biofrontera Inc. — Form 8-K
Filed September 14, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
Biofrontera announced FDA approval (September 14, 2026) of its supplemental NDA for Ameluz (aminolevulinic acid hydrochloride) 10% topical gel combined with BF-RhodoLED lamp for treating superficial basal cell carcinoma (sBCC) in adults. This makes Ameluz the first and only PDT drug approved for skin cancer in the U.S. Phase 3 trial (187 patients) showed 66% complete response with Ameluz vs. 5% with placebo. The company plans launch late Q4 2026 through Q1 2027, targeting an estimated 540,000–720,000 annual sBCC cases in the U.S. (15–20% of 3.6M total BCC cases).
Why this rating
Label expansion to skin cancer is transformational for a $6.9M-market-cap company; first-to-market advantage in PDT oncology, significant addressable market, uses existing infrastructure, but execution and commercialization risk remain.
Tradability signal
NO TRADE
No trade: price $0.02 is below our $0.5 floor — spreads at this level eat any edge.
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $0.02 | +10 min · unknown $0.02 ▲ 0.00% | +30 min · unknown $0.02 ▲ 0.00% | +1 hr · unknown $0.02 ▲ 0.00% | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.